| Identification | Back Directory | [Name]
9-Oxa-4,6,11-triazadodecanoic acid, 3-(1,3-benzodioxol-5-yl)-7-butyl-5,10-dioxo-12-(2-thienyl)-11-(2-thienylmethyl)-, methyl ester, (3S,7S)- | [CAS]
1378532-99-0 | [Synonyms]
THI0019
(3S,7S)-3-(1,3-Benzodioxol-5-yl)-7-butyl-5,10-dioxo-12-(2- thienyl)-11-(2-thienylmethyl)-9-oxa-4,6,11- triazadodecanoic acid methyl ester
9-Oxa-4,6,11-triazadodecanoic acid, 3-(1,3-benzodioxol-5-yl)-7-butyl-5,10-dioxo-12-(2-thienyl)-11-(2-thienylmethyl)-, methyl ester, (3S,7S)-
THI0019 (3S,7S)-3-(1,3-Benzodioxol-5-yl)-7-butyl-5,10-dioxo-12-(2-
thienyl)-11-(2-thienylmethyl)-9-oxa-4,6,11-
triazadodecanoic acid methyl ester | [Molecular Formula]
C29H35N3O7S2 | [MDL Number]
MFCD30527380 | [MOL File]
1378532-99-0.mol | [Molecular Weight]
601.73 |
| Hazard Information | Back Directory | [Description]
THI0019 is an agonist of very late antigen-4 (VLA-4) integrin that induces progenitor cell adhesion. THI0019 greatly enhanced the adhesion of cultured cell lines and primary progenitor cells to α4β1 ligands VCAM-1 and CS1 under both static and flow conditions. Furthermore, THI0019 facilitated the rolling and spreading of cells on VCAM-1 and the migration of cells toward SDF-1α. Molecular modeling predicted that the compound binds at the α/β subunit interface overlapping the ligand-binding site thus indicating that the compound must be displaced upon ligand binding. Co-administering progenitor cells with a compound such as THI0019 may provide a mechanism for enhancing stem cell therapy. |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|